Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genentech Activase

Executive Summary

Results of ASSET (Anglo-Scandinavian Study of Early Thrombolysis) mortality study published in the Sept. 3 issue of The Lancet show overall one month fatality rates with TPA at 7.2% versus 9.8% with placebo in the 5,009 patient study, representing a relative reduction of 26% (95% confidence interval 11-39%). "The 26% reduction of fatality rate is similar to that seen in the ISAM, GISSI, and ISIS-2 trials for streptokinase (12%, 18% and 21%, respectively, or 16%, 20%, and an estimated 27% for patients treated within 6 hours of onset)," the investigators observed. "The effect on 6 month mortality in ASSET will be described later but, by analogy with the late results of GISSI, it seems likely that the difference between groups observed at one month will remain unchanged".

You may also be interested in...

Regulatory Measures Could Mitigate Coronavirus Risks In Europe

As part of its response to the coronavirus outbreak, the European association representing generic and biosimilar drug companies, Medicines for Europe, has set out a series of policy recommendations that it says could help to mitigate the possible risks to medicines supply.

Podcast: Living In China's Coronavirus Lockdown, Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches

Scrip's Brian Yang describes what life is like in China as the authorities battle to contain the coronavirus, and drug developers race to find vaccine and anti-virals against the new threat. Plus news on Novartis' bold initiative with England on inclisiran, and what lies ahead for Biogen and Alzheimer's treatment in 2020

Japan's BioComo Pursues Novel Ligand Approach To Immuno-Oncology

Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts